Patients with glioma were divided into different groups based on different clinical characteristics for age (age<42, age≥42), gender (female, male), grade (WHO 2, WHO 3, and WHO 4), IDH (mutant, wild type), 1p19q (codel, non-codel), and MGMT (methylated, un-methylated) status. This evidence concerns the gene MGMT and glioma.